Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

A user shared their 88-day progress using 1.25mg finasteride, topical minoxidil, and weekly 1mm microneedling, noting improvement from NW 4.5 to around NW 3. Another user complimented the progress.

The conversation discusses the use of dutasteride (DUT) versus finasteride (FIN) for hair loss treatment, with some users preferring DUT for its effectiveness while others choose FIN due to its approval status, better long-term data, and lower risk of side effects. Users share personal experiences with both medications, including side effects and effectiveness.

The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.

The user switched from finasteride to dutasteride for hair loss treatment, also using topical minoxidil, micro needling, keto shampoo, and PRP sessions. They've seen improvements, with reduced hair shedding and new hair growth, especially at the hairline.

The conversation discusses GT20029 as a potential hair loss treatment that could act like a cure by targeting androgen receptors in scalp hair follicles. Specific treatments mentioned include GT20029, with a user expressing hope that it could make male pattern baldness obsolete.

The user plans to improve hair density using Koshine, Avodart (1.5-2.5mg daily), and 5mg OM daily. They previously used finasteride, minoxidil, dutasteride, and fluridil with some improvement.

The user has been using finasteride and topical minoxidil since 2020 with good initial results, but progress has stalled since 2024. They are considering switching to dutasteride and oral minoxidil for better results.

The user switched from finasteride to dutasteride 0.5mg daily two years ago and has experienced hair maintenance and slight thickening without side effects. The user's libido increased after switching, and they are not using minoxidil.

People are hopeful for a permanent hair loss solution by the 2030s, considering options like hair cloning and treatments like pp405. Synthetic hair transplants have been attempted but are not effective long-term.

The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.

The user started using EssenGen 6-Plus, containing 6% minoxidil and 0.05% finasteride, along with 1% Nizoral shampoo, and reported noticeable hair growth in 7 weeks. They experienced some chest tightness but are monitoring it, and they are satisfied with the progress despite using a silicone-containing shampoo.

The conversation is about hair loss treatments, specifically using Dutasteride and Minoxidil since November 2025, with positive progress reported. Users discuss the effectiveness and side effects of topical and oral Minoxidil and Finasteride, with some preferring topical solutions to avoid side effects.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.

The user experienced hair recovery using oral dutasteride 0.5 mg and oral minoxidil 5 mg daily, considering increasing dutasteride dosage but concerned about cost and effectiveness. They noted progress and discussed alternatives like hair transplants and other medications.

The user is experiencing hair miniaturization despite using dutasteride 0.5mg daily and oral minoxidil 3mg daily for three months. They are advised to continue the treatment as full effects may take up to a year.

The conversation discusses the potential of developing a selective oral SARM to target androgen activity in the scalp and skin, as an alternative to oral Dutasteride and Finasteride, which have systemic side effects. It also mentions Clascoterone and RU58841 as topical treatments for hair loss.

The user is experiencing progress in hair regrowth using 1 mg finasteride and 5 mg minoxidil, with no side effects reported. There is a discussion about whether to switch from finasteride to dutasteride, but many advise against it since finasteride is showing good results.

The user has been using 0.5mg daily dutasteride for a year without seeing progress and previously used oral finasteride and topical minoxidil. They are considering a hair transplant and discussing various treatments like scalp massages, derma rolling, and different medication dosages.

Significant hair regrowth was achieved using EssenGen 6-Plus with 6% minoxidil and 0.05% finasteride, along with Nizoral shampoo, over 12 weeks. No side effects were experienced, highlighting the benefits of a low dose.

People are sharing their experiences of keeping a hidden folder on their phones with photos documenting their hair loss. Some users discuss the emotional impact, while one mentions using dutasteride and oral minoxidil without noticeable change.

A 22-year-old male shares his 2-month progress using a regimen of 0.5mg dutasteride daily, 1.5mm dermarolling weekly, a daily multivitamin, and a topical serum with 10% minoxidil and 0.1% finasteride. He reports impressive hair regrowth, especially at the hairline, and has experienced no sexual side effects.

After over a year of treatment with daily oral dutasteride and minoxidil, plus injected dutasteride every 6 months, the user is happy with the increased thickness of their hair and improved self-esteem, although scalp visibility remains. They encourage others to follow similar treatments for long-term hair maintenance.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

A user's 8-month progress with Fin/Min/Dermarolling treatments for hair loss, which have resulted in great improvements to the user's temples.

The conversation is about a user's one-year hair regrowth progress using 1.25mg of finasteride daily. Users are asking about the timeline of visible progress, the user's age, and whether they experienced shedding.

User shared 3.5 months progress on oral finasteride 1.25mg daily with no side effects. Other users commented on the effectiveness and shared their experiences.